Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Public ClinicalTrials.gov record NCT04638660. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this study are: * To evaluate the efficacy of Nyxol to improve mesopic low contrast visual acuity (mLCVA) in subjects with Dim Light Vision Disturbances (DLD) * To evaluate efficacy of Nyxol to improve visual performance * To evaluate the safety of Nyxol
Study identification
- NCT ID
- NCT04638660
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 144 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 30, 2020 (Actual)
- Primary completion
- May 19, 2022 (Actual)
- Completion
- May 19, 2022 (Actual)
- Last update posted
- Oct 14, 2025
2020 – 2022
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site 6 | Newport Beach | California | 92663 | — |
| Clinical Site 1 | Petaluma | California | 94954 | — |
| Clinical Site 3 | Jacksonville | Florida | 32204 | — |
| Clinical Site 18 | Jacksonville | Florida | 32256 | — |
| Clinical Site 13 | Pittsburg | Kansas | 66762 | — |
| Clinical Site 20 | Edgewood | Kentucky | 41017 | — |
| Clinical Site 14 | Louisville | Kentucky | 41008 | — |
| Clinical Site 10 | Palisades Park | New Jersey | 07650 | — |
| Clinical Site 8 | Pennington | New Jersey | 08534 | — |
| Clinical Site 4 | Elizabeth City | North Carolina | 27909 | — |
| Clinical Site 22 | High Point | North Carolina | 27262 | — |
| Clinical Site 9 | High Point | North Carolina | 27262 | — |
| Clinical Site 2 | Fargo | North Dakota | 58103 | — |
| Clinical Test 15 | Warwick | Rhode Island | 57108 | — |
| Clinical Site 11 | Memphis | Tennessee | 38119 | — |
| Clinical Site 5 | San Antonio | Texas | 78240 | — |
| Clinical Site 19 | Ogden | Utah | 84403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04638660, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04638660 live on ClinicalTrials.gov.